105 related articles for article (PubMed ID: 38804896)
1. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Wong S; Kwan ATH; Rhee TG; Teopiz KM; Ho R; Cao B; Mansur RB; Rosenblat JD; Le GH
Expert Opin Drug Saf; 2024 Jun; ():1-5. PubMed ID: 38804896
[TBL] [Abstract][Full Text] [Related]
2. The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Mansur RB; Rosenblat JD; Teopiz KM; Kwan ATH
Expert Opin Drug Saf; 2024 Jun; ():1-6. PubMed ID: 38884147
[TBL] [Abstract][Full Text] [Related]
3. Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis.
Xue T; Wu X; Li J; Chen S; Wang Z; Tan X; Wang Z; Zhang J
Front Pharmacol; 2023; 14():1175372. PubMed ID: 37261282
[No Abstract] [Full Text] [Related]
4. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Mansur RB; Rosenblat JD; Kwan ATH
Expert Opin Drug Saf; 2024 Jan; 23(1):47-55. PubMed ID: 38087976
[TBL] [Abstract][Full Text] [Related]
5. Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system.
Wong S; Le GH; Kwan ATH; Rhee TG; Teopiz KM; Ho RC; Cao B; Rosenblat JD; Mansur R; McIntyre RS
Int Clin Psychopharmacol; 2024 May; ():. PubMed ID: 38727416
[TBL] [Abstract][Full Text] [Related]
6. Safety of Dual Orexin Receptor Antagonist Daridorexant: A Disproportionality Analysis of Publicly Available FAERS Data.
Cicala G; Barbieri MA; Russo G; Salvo F; Spina E
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543128
[TBL] [Abstract][Full Text] [Related]
7. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
8. Clinical safety and narcolepsy-like symptoms of dual orexin receptor antagonists in patients with insomnia: a systematic review and meta-analysis.
Na HJ; Jeon N; Staatz CE; Han N; Baek IH
Sleep; 2024 Feb; 47(2):. PubMed ID: 37950346
[TBL] [Abstract][Full Text] [Related]
9. Newer Antiseizure Medications and Suicidality: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Leppien EE; Doughty BJ; Hurd KL; Strong KN; Piper BJ; McCall KL
Clin Drug Investig; 2023 Jun; 43(6):393-399. PubMed ID: 37184612
[TBL] [Abstract][Full Text] [Related]
10. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
Ufer M; Kelsh D; Schoedel KA; Dingemanse J
Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
[TBL] [Abstract][Full Text] [Related]
11. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).
Kwan ATH; Rosenblat JD; Mansur RB; Teopiz KM; McIntyre RS
J Affect Disord; 2024 Sep; 360():421-426. PubMed ID: 38795777
[TBL] [Abstract][Full Text] [Related]
12. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
[TBL] [Abstract][Full Text] [Related]
13. Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System.
Barbieri MA; Russo G; Sorbara EE; Cicala G; Franchina T; Santarpia M; Speranza D; Spina E; Silvestris N
Front Oncol; 2023; 13():1268672. PubMed ID: 38023143
[TBL] [Abstract][Full Text] [Related]
14. The abuse potential of lemborexant, a dual orexin receptor antagonist, according to the 8 factors of the Controlled Substances Act.
Moline M; Asakura S; Beuckman C; Landry I; Setnik B; Ashworth J; Henningfield JE
Psychopharmacology (Berl); 2023 Apr; 240(4):699-711. PubMed ID: 36749354
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the delirium preventive effect of dual orexin receptor antagonist (DORA) in critically ill adult patients requiring ventilation with tracheal intubation at an advanced emergency center: A single-center, retrospective, observational study.
Matsuoka A; Sogawa R; Murakawa-Hirachi T; Mizoguchi Y; Monji A; Shimanoe C; Shinada K; Koami H; Sakamoto Y
Gen Hosp Psychiatry; 2023; 83():123-129. PubMed ID: 37182281
[TBL] [Abstract][Full Text] [Related]
16. Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant.
Khazaie H; Sadeghi M; Khazaie S; Hirshkowitz M; Sharafkhaneh A
Front Psychiatry; 2022; 13():1070522. PubMed ID: 36578296
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis.
Xue T; Wu X; Chen S; Yang Y; Yan Z; Song Z; Zhang W; Zhang J; Chen Z; Wang Z
Sleep Med Rev; 2022 Feb; 61():101573. PubMed ID: 34902823
[TBL] [Abstract][Full Text] [Related]
18. No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database.
Napoli AA; Wood JJ; Coumbis JJ; Soitkar AM; Seekins DW; Tilson HH
J Int AIDS Soc; 2014; 17(1):19214. PubMed ID: 25192857
[TBL] [Abstract][Full Text] [Related]
19. Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis.
Jiang A; Wei C; Zhu W; Wu F; Wu B
Ther Adv Drug Saf; 2024; 15():20420986241244585. PubMed ID: 38715707
[TBL] [Abstract][Full Text] [Related]
20. Emerging and upcoming therapies in insomnia.
Kim WJ; Kim HS
Transl Clin Pharmacol; 2024 Mar; 32(1):1-17. PubMed ID: 38586124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
